Meeting News CoverageVideo

VIDEO: Juan F. Granada, MD, points to innovations shifting the landscape of interventional cardiology

SAN FRANCISCO — Interventional cardiologist Juan F. Granada, MD, executive director and chief innovation officer of the Cardiovascular Research Foundation’s Skirball Center for Innovation, provides an overview of new technologies that took center stage at TCT 2015.

He highlights “extremely exciting” findings on the everolimus-eluting bioresorbable vascular scaffold (Absorb, Abbott Vascular) in patients with target lesion failure from the ASBORB III trial. “This study is going to be a landmark, and it’s going to serve for the design of new-generation trials and devices in the future,” Granada said.

He also discuss new approaches to treat mitral regurgitation, noting that the spotlight was on valve replacement at the meeting and emphasizing “the potential reality of these technologies to become mainstay therapy.”

Granada highlights the “aggressive motion” currently being witnessed in the arena of transcatheter aortic valve replacement. “It’s right now moving at a very steady pace, devices are getting smaller and more stable, and the clinical outcomes continue to improve,” he said.

Lastly, Granada covers the “Shark Tank Innovation Competition” that featured the top technologies selected from several dozen submissions, pointing to specific advances in the field of vascular pulmonary intervention.

SAN FRANCISCO — Interventional cardiologist Juan F. Granada, MD, executive director and chief innovation officer of the Cardiovascular Research Foundation’s Skirball Center for Innovation, provides an overview of new technologies that took center stage at TCT 2015.

He highlights “extremely exciting” findings on the everolimus-eluting bioresorbable vascular scaffold (Absorb, Abbott Vascular) in patients with target lesion failure from the ASBORB III trial. “This study is going to be a landmark, and it’s going to serve for the design of new-generation trials and devices in the future,” Granada said.

He also discuss new approaches to treat mitral regurgitation, noting that the spotlight was on valve replacement at the meeting and emphasizing “the potential reality of these technologies to become mainstay therapy.”

Granada highlights the “aggressive motion” currently being witnessed in the arena of transcatheter aortic valve replacement. “It’s right now moving at a very steady pace, devices are getting smaller and more stable, and the clinical outcomes continue to improve,” he said.

Lastly, Granada covers the “Shark Tank Innovation Competition” that featured the top technologies selected from several dozen submissions, pointing to specific advances in the field of vascular pulmonary intervention.

    See more from Highlights from TCT